NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Public ClinicalTrials.gov record NCT06450041. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Study identification
- NCT ID
- NCT06450041
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Interventions
- Dinutuximab Drug
- GM-CSF Drug
- Irinotecan Drug
- Temozolomide Drug
- Universal Donor (UD) TGFβi NK Cells Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 31 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2024
- Primary completion
- Nov 30, 2028
- Completion
- Nov 30, 2038
- Last update posted
- Mar 22, 2026
2024 – 2038
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Los Angeles | Los Angeles | California | 90027-0700 | Recruiting |
| UCSF Benioff Children's Hospital | San Francisco | California | 94143 | Not yet recruiting |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | Not yet recruiting |
| Comer Children's Hospital, University of Chicago | Chicago | Illinois | 60614 | Not yet recruiting |
| Boston Children's Hospital, Dana-Farber Cancer Institute. | Boston | Massachusetts | 02115 | Not yet recruiting |
| C.S Mott Children's Hospital | Ann Arbor | Michigan | 48109 | Not yet recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229-3039 | Not yet recruiting |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | Not yet recruiting |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104-4318 | Recruiting |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Not yet recruiting |
| University of Texas Southwestern | Dallas | Texas | 75235 | Recruiting |
| Cook Children's Medical Center | Fort Worth | Texas | 76104 | Recruiting |
| Seattle Children's Hospital | Seattle | Washington | 98105 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06450041, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06450041 live on ClinicalTrials.gov.